Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0000000000209581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Intravenous Thrombolysis by Infarct Type in Patients with No Visible Occlusion: A Secondary Analysis of the AcT Trial.
J Am Heart Assoc
December 2024
Division of Neurology, Rady Faculty of Health Sciences University of Manitoba Winnipeg MB Canada.
Background: About 25% of patients with acute ischemic stroke have lacunar infarct on follow-up imaging. In this secondary analysis from the AcT (Alteplase Compared With Tenecteplase) trial, we assessed if there is variation in safety or efficacy of intravenous thrombolysis by infarct type in patients with no visible occlusion. We also determined if this effect differed between tenecteplase and alteplase.
View Article and Find Full Text PDFTenecteplase thrombolytic therapy for acute ischaemic stroke in China: a real-world, multicentre, retrospective, controlled study.
Stroke Vasc Neurol
November 2024
Department of Neurology, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, China.
Background And Aims: Tenecteplase (TNK) offers logistical advantages in stroke thrombolytic therapy with its single bolus administration compared with alteplase. We aim to investigate the real-world evidence regarding its safety and effectiveness in China.
Methods: We conducted a retrospective study on patients receiving alteplase or TNK for acute ischaemic stroke (AIS) within 4.
A telemedicine-enabled intravenous thrombolytic treatment pathway for patients with hyperacute non-arteritic central retinal artery occlusion.
Am J Ophthalmol Case Rep
December 2024
Kaiser Permanente Northern California, Department of Ophthalmology, Oakland, CA, USA.
Purpose: To describe the visual acuity (VA) outcomes from a telemedicine-enabled pathway allowing for rapid diagnosis and administration of intravenous (IV) thrombolytic treatment for non-arteritic central retinal artery occlusion (naCRAO) within 4.5 hours (4.5 h) of visual loss.
View Article and Find Full Text PDFBibliometric analysis of the usage of tenecteplase for stroke.
Int J Emerg Med
November 2024
Orlando College of Osteopathic Medicine, Winter, FL, 34787, USA.
Introduction: In recent years, tenecteplase has been competing with alteplase as a treatment for acute ischemic stroke given its ease of administration, lower dosage, cost-effectiveness, and better safety data. This paper seeks to analyze academic literature regarding the burgeoning usage of tenecteplase as a treatment for acute ischemic stroke across the world.
Method: The Web of Science database was used to collect the data from articles containing the keywords "Tenecteplase" and "Stroke" published from 1999 to 2023.
Background: In large vessel occlusion (LVO) stroke patients transferred to a comprehensive stroke center for thrombectomy, spontaneous reperfusion may occur during transport, and anecdotally more frequently in patients transferred via helicopter than by ground. This pattern has been more often observed in conjunction with tenecteplase (TNK) treatment prior to helicopter transport. We aim to explore the "chopperlysis" effect-how helicopter transport, particularly with thrombolytics, may affect reperfusion and clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!